Breaking News, Collaborations & Alliances

Charles River & Axovia Partner to Support Development of Gene Therapies for Ciliopathies

Axovia will leverage Charles River’s plasmid platform and expertise in plasmid DNA production to accelerate time to clinic.

Author Image

By: Charlie Sternberg

Associate Editor

Charles River Laboratories International Inc. has announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd. under which Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.   Ciliopathies are diseases caused by cilia dysfunction, which is a ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters